Cytochromes P450

Psychopharmacogenetics

Volumn , Issue , 2006, Pages 443-478

  Dahl, Marja Liisa ^a   Scordo, Maria Gabriella ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67650765007     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-34577-2_16     Document Type: Chapter

References (228)

1. Agundez, J. A., Ledesma, M. C., Ladero, J. M. et al., 1995, Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population, Clin. Pharmacol. Ther. 57, 265-269.
2. Aitchison, K. J., Munro, J., Wright, P. et al., 1999, Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation, Br. J. Clin. Pharmacol. 48, 388-394.
3. Alexanderson, B., Evans, D. A., Sjöqvist, F., 1969, Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy, Br. Med. J. 4, 764-768.
4. Alvan, G., Bechtel, P., Iselius, L. et al., 1990, Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations, Eur. J. Clin. Pharmacol. 39, 533-537.
5. Andreassen, O. A., Macewan, T., Gulbrandsen, A. K., Mccreadie, R. G., Steen, V. M., 1997, Nonfunctional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients, Psychopharmacology. 131, 174-179.
6. Armstrong, M., Daly, A. K., Blennerhassett, R., Ferrier, N., Idle, J., 1997, Antipsychotic druginduced movement disorders in schizophrenics in relation to CYP2D6 genotype, Br. J. Psychiatry. 170, 23-26.
7. Arthur, H., Dahl, M. L., Siwers, B., Sjöqvist, F., 1995, Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia, J. Clin. Psychopharmacol. 15, 211-216.
8. Avenoso, A., Spina, E., Campo, G. et al., 1997, Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications, Pharmacol. Res. 35, 335-339.
9. Barbhaiya, R. H., Buch, A. B., Greene, D. S., 1996, Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan, Br. J. Clin. Pharmacol. 42, 573-581.
10. Basile, V. S., Özdemir, V., Masellis, M. et al., 2000, A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia, Mol. Psychiatry 5, 410-417.
11. Baumann, P., Jonzier Perey, M., Koeb, L., Küpfer, A., Tinguely, D., Schopf, J., 1986, Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin, Int. Clin. Psychopharmacol. 1, 102-112.
12. Berecz, R., De La Rubia, Dorado, A. P., Fernandez-Salguero, P., Dahl, M. L., Llerena, A., 2003, Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype, Eur. J. Clin. Pharmacol. 59(1), 45-50.
13. Bernal, M. L., Sinues, B., Johansson, I. et al., 1999, Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine, Pharmacogenetics. 9, 657-660.
14. Bertilsson, L., Åberg-Wistedt, A., Gustafsson, L. L., Nordin, C., 1985, Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants, Ther. Drug Monit. 7, 478-480.
15. Bertilsson, L., Carrillo, J. A., Dahl, M. L. et al., 1994, Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test, Br. J. Clin. Pharmacol. 38, 471-473.
16. Bertilsson, L., Dahl, M. L., Sjöqvist, F., Åberg-Wistedt, A., Humble, M., Johansson, I., Lundqvist, E., Ingelman-Sundberg, M., 1993, Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter], Lancet. 341, 63.
17. Bertilsson, L., Dahl, M.-L., Dalén, P., Al-Shurbaji, A., 2002, Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs, Br. J. Clin. Pharmacol. 53, 111-122.
18. Bertilsson, L., Lou, Y., Q., Du, Y. L. et al., 1992, Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin, Clin. Pharmacol. Ther. 51, 388-397.
19. Bertilsson, L., Mellström, B., Sjöqvist, F., Martenson, B., Åsberg, M., 1981, Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications [letter], Lancet. 1, 560-561.
20. Bloomer, J. C., Woods, F. R., Haddock, R. E., Lennard, M. S., Tucker, G. T., 1992, The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes, Br. J. Clin. Pharmacol. 33, 521-523.
21. Bork, J. A., Rogers, T., Wedlund, P. J. et al., 1999, A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A, J. Clin. Psychiatry. 60, 469-476.
22. Brachtendorf, L., Jetter, A., Beckurts, K. T., Hölscher, A. H., Fuhr, U., 2002, Cytochrome P-450 enzymes contributing to demethylation of maprotiline in man, Pharmacology & Toxicology. 90, 144-149.
23. *3 metabolizer, Clin. Pharmacol. Ther. 70, 391-394.
24. Brockmoller, J., Kirchheiner, J., Schmider, J., Walter, S., Sachse, C., Muller-Oerlinghausen, B., Roots, I., 2002, The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment, Clin. Pharmacol. Ther. 72, 438-452.
25. Broly, F., Gaedigk, A., Heim, M., Eichelbaum, M., Morike, K., Meyer, U. A., 1991, Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population, DNA Cell. Biol. 10, 545-558.
26. Brøsen, K., Gram, L. F., Klysner, R., Bech, P., 1986, Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics, Eur. J. Clin. Pharmacol. 30, 43-49.
27. Brøsen, K., Klysner, R., Gram, L. F., Otton, S. V., Bech, P., Bertilsson, L., 1986, Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism, Eur. J. Clin. Pharmacol. 30, 679-684.
28. Caccia, S., 1998, Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications, Clin. Pharmacokinet. 34, 281-302.
29. Caccia, S., 2000, Biotransformation of post-clozapine antipsychotics: pharmacological implications, Clin. Pharmacokinet. 38, 393-414.
30. Callaghan, J. T., Bergstrom, R. F., Ptak, L. R., Beasley, C. M., 1999, Olanzapine: pharmacokinetic and pharmacodynamic profile, Clin. Pharmacokinet. 37, 177-193.
31. Carrillo, J. A., Dahl, M. L., Svensson, J. O., Alm, C., Rodriguez, I., Bertilsson, L., 1996, Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity, Clin. Pharmacol. Ther. 60, 183-190.
32. Carrillo, J. A., Ramos, S. I., Herraiz, A. G. et al., 1999, Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients, J. Clin. Psychopharmacol. 19, 494-499.
33. Centorrino, F., Baldessarini, R. J., Frankenburg, F. et al., 1996, Serum levels of clozapine and norclozapine in patients treated with selective serotonin re-uptake inhibitors, Am. J. Psychiatry. 153, 820-822.
34. Centorrino, F., Baldessarini, R. J., Kando, J., Frankenburg, F. R., Volpicelli, S. A., Flood, J. G., 1994, Serum concentrations of clozapine and its metabolites: effects of cotreatment with fluoxetine or valproate, Am. J. Psychiatry. 151, 123-125.
35. Chang, M., Dahl, M. L., Tybring, G., Gotharson, E., Bertilsson, L., 1995, Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype, Pharmacogenetics. 5, 358-363.
36. Chiba, K., Saitoh, A., Koyama, E., Tani, M., Hayashi, M., Ishizaki, T., 1994, The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation, Br. J. Clin. Pharmacol. 37, 237-242.
37. Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J., Kamataki, T., 1999, Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population, Jpn. J. Cancer Res. 90, 899-902.
38. Chou, W. H., Yan, F. X., De Leon, J. et al., 2000, Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness, J. Clin. Psychopharmacol. 20, 246-251.
39. Cohen, L. G., Chesley, S., Eugenio, L., Flood, J. G., Fisch, J., Goff, D. C., 1996, Erythromycininduced clozapine toxic reaction, Arch. Int. Med. 156, 675-677.
40. Dahl, M. L., Bertilsson, L., Nordin, C., 1996, Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype, Psychopharmacology (Berl). 123, 315-319.
41. Dahl, M. L., Ekqvist B., Widen, J., Bertilsson, L., 1991, Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans, Acta Psychiatr. Scand. 84, 99-102.
42. Dahl, M. L., Iselius, L., Alm, C., Svensson, J. O., Lee, D., Johansson, I., Ingelman-Sundberg, M., Sjoqvist F., 1993, Polymorphic 2-hydroxylation of desipramine. A population and family study, Eur. J. Clin. Pharmacol. 44, 445-450.
43. Dahl, M. L., Johansson, I., Bertilsson, L. et al, 1995, Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis, J. Pharmacol. Exp. Ther. 274, 516-520.
44. Dahl, M. L., Johansson, I., Palmertz, M. P., Ingelman-Sundberg, M., Sjöqvist, F., 1992, Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population, Clin. Pharmacol. Ther. 51, 12-17.
45. Dahl, M. L., Llerena, A., Bondesson, U. et al., 1994, Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms, Br. J. Clin. Pharmacol. 37, 71-74.
46. Dahl, M. L., Tybring, G., Elwin, C. E., Alm, C., Andreasson, K., Gyllenpalm, M., Bertilsson, L., 1994, Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism. Clin. Pharmacol. Ther. 56, 176-183.
47. Dahl, M. L., Voortman, G., Alm, C., Elwin, C. E., Delbressine, L., Vos, R., Bogaards, J. J. P., Bertilsson, L., 1997, In vitro and in vivo studies on the disposition of mirtazapine in humans, Clin. Drug Invest. 13, 37-46.
48. Dahl, M.-L., 2002, Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics. Useful aid to prescribing? Clin. Pharmacokinet. 41(7), 453-470.
49. Dahl, S. G., 1982, Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects, Ther. Drug Monit. 4, 33-40.
50. Dahl-Puustinen, M. L., Liden, A. Alm, C., Nordin, C., Bertilsson, L., 1989, Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings, Clin. Pharmacol. Ther. 46, 78-81.
51. Dalén, P., Dahl, M. L., Ruiz, M. L., Nordin, J., Bertilsson, L., 1998, 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes, Clin. Pharmacol. Ther. 63, 444-452.
52. Daniel, D. G., Randolph, C., Jaskiw, G. et al., 1994, Coadministration of fluvoxamine increases serum concentrations of haloperidol, J. Clin. Psychopharmacol. 14, 340-343.
53. De Jong, J., Hoogenboom, B., Van Troostwijck, L. D., De Hann, L., 2001, Interaction of olanzapine with fluvoxamine, Psychopharmacology. 156, 219-220.
54. De Morais, S. M., Wilkinson, G. R., Blaisdell, J. et al., 1994, Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese, Mol. Pharmacol 46, 594-598.
55. De Morais, S. M., Wilkinson, G. R., Blaisdell, J. et al., 1994, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, J. Biol. Chem. 269, 15419-15422.
56. Delbressine, L. P., Vos, R. M., 1997, The clinical relevance of preclinical data: Mirtazapine, a model compound, J. Clin. Psychopharmacol. 17, 29S-33S.
57. Desai, H. D., Seabolt, J., Jann, M. W., 2001, Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective, CNS Drugs. 15, 469-494.
58. Dev, V., Raniwalla, J., 2000, Quetiapine: a review of its safety in the management of schizophrenia, Drug Saf 23, 295-307.
59. Devane, C. L., Nemeroff, C. B., 2001, Clinical pharmacokinetics of quetiapine: an atypical antipsychotic, Clin. Pharmacokinet. 40, 509-522.
60. Dodd, S., Boulton, D. W., Burrows, G. D., DeVane, C. L., Norman, T. R., 2001, In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes, Hum. Psychopharmacol. Clin. Exp. 16, 541-544.
61. Eap, C. B., Bondolfi, G., Zullino, D., Savary-Cosendai, L., Powell-Golay, K., Kosel, M., Baumann, P., 2001, Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers, J. Clin. Psychopharmacol. 21, 330-334.
62. Eap, C. B., Lessard, E., Baumann, P., Brawand-Amey, M., Yessine, M.-A., O'Hara, G., Turgeon, J., 2003, Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans, Pharmacogenetics. 13, 39-47.
63. Eap, C. B., Lima, C. A., Macciardi, F., Woggon, B., Powell, K., Baumann, P., 1998, Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine, Ther. Drug. Monit. 20(1), 7-13.
64. Eap, C. B., Guentert, T. W., Schaublin M., Loidl et al., 1996, Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin, Clin. Pharmacol. Ther. 59, 322-331.
65. Eichelbaum, M., Spannbrucker, N., Steincke, B. et al., 1979, Defective N-oxidation of sparteine in man: a new pharmacogenetic defect, Eur. J. Clin. Pharmacol. 16, 183-187.
66. Eiermann, B., Engel, G., Johansson, I. et al., 1997, The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine, Br. J. Clin. Pharmacol. 44, 439-446.
67. Evans, D. A., Mahgoub, A., Sloan, T. P. et al., 1980, A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population, J. Med. Genet. 17, 102-105.
68. Fang, J., Baker, G. B., Silverstone, P. H. et al., 1997, Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol, Cell. Mol. Neurobiology. 17, 227-233.
69. Fang, J., Bourin, M., Baker, G. B., 1999, Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4, Naunyn- Schmiedeberg's Arch. Pharmacol. 359, 147-151.
70. Fang, J., Gorrod, J. W., 1999, Metabolism, pharmacogenetics and metabolic drug-drug interactions of antipsychotic drugs, Cell. Mol. Neurobiol. 19, 491-510.
71. Firkusny, L., Gleiter, C. H., 1994, Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. Br. J. Clin. Pharmacol. 37, 383-388.
72. Fischer, V., Vogels, B., Maurer, G. et al., 1992, The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6, J. Pharmacol. Exp. Ther. 260, 1355-1360.
73. Fjordside, L., Jeppesen, U., Eap, C. B., Powell, K., Baumann, P., Brøsen, K., 1999, The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine, Pharmacogenetics. 9, 55-60.
74. Fogelman, S. M., Schmider, J., Venkatakrishnan, K., Von Moltke, L. L., Harmatz, J. S., Shader, R. I., Greenblatt, D. J., 1999, O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants, Neuropsychopharmacol. 20, 480-490.
75. Fukuda, T., Nishida, Y., Zhou, Q., Yamamoto, I., Kondo, S., Azuma, J., 2000, The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population, Eur. J. Clin. Pharmacol. 56, 175-180.
76. Funderburg, L. G., Vertrees, J. E., True, J. E., Miller, A. L., 1994, Seizure following addition of erythromycin to clozapine therapy, Am. J. Psychiatry. 151, 1840-1841.
77. Gaedigk, A., Blum, M., Gaedigk, R., Eichelbaum, M., Meyer, U. A., 1991, Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism, Am. J. Hum. Genet. 48, 943-950.
78. Goldstein, J. A., 2001, Clinical relevance of genetic polymorphisms in the human CYP2C subfamily, Br. J. Clin. Pharmacol. 52, 349-355.
79. Gonzales, F. J., 1992, Human cytochrome P450: problems and prospects, Trends Pharmacol. Sci. 13, 346-352.
80. Gram, L. F., 1977, Plasma level monitoring of tricyclic antidepressant therapy, Clin. Pharmacokinet. 2, 237-251.
81. Gram, L. F., Guentert, T. W., Grange, S., Vistisen, K., Brøsen, K., 1995, Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin. Pharmacol. Ther. 57, 670-677.
82. Guengerich, F. P., 1995, Human cytochrome P450 enzymes. In: Cytochrome P450: structure, mechanism, and biochemistry, Ortiz De La Montellano PR (Ed.), Plenum Press, New York, 473-535.
83. Güsey, C., Aamo, T., Spigset, O., 2000, Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer, J. Clin. Psychiatry. 61, 600-601.
84. Hagg, S., Spigset, O., Mjorndal, T., Granberg, K., Persbo-Lundqvist, G., Dahlqvist, R., 1999, Absence of interaction between erythromycin and a single dose of clozapine, Eur. J. Clin. Pharmacol. 55, 221-226.
85. Hale, P., Poklis, A., 1996, Thioridazine cardiotoxicity, J. Toxicol. Clin. Toxicol. 34, 127-130.
86. Hamelin, B. A., Turgeon, J., Vallee, F., Belanger, P. M., Paquet, F., LeBel, M., 1996, The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin. Pharmacol. Ther. 60, 512-521.
87. Hammer, W., Sjöqvist, F., 1967, Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds, Life Sci. 6, 1895-1903.
88. Haring, C., Fleischhacker, W., Schett, P., Humpel, C., 1990, Influence of plasma related variables on clozapine levels, Am. J. Psychiatry. 147, 1471-1475.
89. Härtter, S., Dingemanse, J., Baijer, D., Ziegler, G., Hiemke, C., 1996, The role of cytochrome P450 2D6 in the metabolism of moclobemide, Eur. Neuropsychopharmacol. 6(3), 225-230.
90. Hasegawa, M., Guiterrez, R., Way, L., Meltzer, H. Y., 1993, Relationship between clinical efficacy and clozapine concentration in plasma in schizophrenia: effect of smoking, J. Clin. Psychopharmacol. 13, 383-390.
91. Hiemke, C., Weigmann, H., Härtter, S. et al., 1994, Elevated levels of clozapine in serum after addition of fluvoxamine, J. Clin. Psychopharmacol. 14, 279-281.
92. Holliday, S. M., Benfield, P., 1995, Venlafaxine - a review of its pharmacology and therapeutic potential in depression, Drugs. 49, 280-294.
93. Hoskins, J., Shenfield, G., Murray, M., Gross, A., 2001, Characterization of moclobemide N-oxidation in human liver microsomes, Xenobiotica. 31(7), 387-397.
94. Huang, M. L., Van Peer, A., Woestenborghs, R. et al., 1993, Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects, Clin. Pharmacol. Ther. 54, 257-268.
95. Hubbard, J. W., Midha, K. K., Hawe, E. M. et al., 1993, Metabolism of phenothiazine and butyrophenone antipsychotic drugs: a review of some recent research findings and clinical implications, Br. J. Psychiatry. 163, 19-24.
96. Ingelman-Sundberg, M., Oscarsson, M., McLellan, R. A., 1999, Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment, Trends Pharmacol. Sci. 20, 342-349 (1999).
97. Ishida, M., Otani, K., Kaneko S., Ohkubo, T., Osanai, T., Yasui N., Mihara, K., Higuchi H., Sugawara, K., 1995, Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int. Clin. Psychopharmacol. 10, 143-146.
98. Jaanson, P., Marandi, T., Kiivet, R. A., Vasar, V., Vään, S., Svensson, J. O., Dahl, M. L., 2002, Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype, Psychopharmacol. 162, 67-73.
99. Jan, M. W., ZumBrunnen, T. L., Kazmi, Y. R., VanDenBerg, C. M., Desai,. H. D., Weidler, D. J., Flockhart, D. A., 2002, Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype, Drug. Metabol. Drug. Interact. 19(1), 1-11.
100. Jerling, M., Dahl, M. L., Åberg-Wistedt, A. et al., 1996, The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol, Clin. Pharmacol. Ther. 59, 423-428.
101. Joergensen, A., 1986, Metabolism and pharmacokinetics of antipsychotic drugs, Prog. Drug Metabolism. 9, 111-174.
102. Johansson, I., Lundqvist, E., Bertilsson, L. et al., 1993, Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine, Proc. Natl. Acad. Sci. USA. 90, 11825-11829.
103. Johansson, I., Oscarson, M., Yue, Q. Y. et al., 1994, Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation, Mol. Pharmacol. 46, 452-459.
104. Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T., Meyer, U. A., 1990, Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes, J. Biol. Chem. 265, 17209-17214.
105. Kassahun, K., Mattiuz, E., Nyhart, E. et al., 1997, Disposition and biotransformation of the antipsychotic agent olanzapine in humans, Drug Metab. Dispos. 25, 81-93.
106. Kirchheiner, J., Brøsen, K., Dahl, M.-L., Gram L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., Brockmöller, J., 2001, CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages, Acta. Psychiatr. Scand. 104, 173-192.
107. Kobayashi, K., Chiba, K., Yagi, T., Shimada, N., Taniguchi, T., Horie, T., Tani, M., Yamamoto, T., Ishizaki, T., Kuroiwa, Y., 1997, Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes, J. Pharmacol. Exp. Ther. 280, 927-933.
108. Kobayashi, K., Ishizuka, T., Shimada, N., Yoshimura, Y., Kamijima, K., Chiba, K., 1999, Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro, Drug Metab. Dispos. 27, 763-766.
109. Koyama, E., Chiba, K., Tani, M., Ishizaki, T., 1996, Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers, J. Pharmacol. Exp. Ther. 278, 21-30.
110. Koyama, E., Tanaka, T., Chiba, K., Kawakatsu, S., Morinobu, S., Totsuka, S., Ishizaki, T., 1996, Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients, J. Clin. Psychopharmacol. 16, 286-293.
111. Kuo, F. J., Lane, H. Y., Chang, W. H., 1998, Extrapyramidal symptoms after addition of fluvoxamine to clozapine, J. Clin. Psychopharmacol. 53, 483-484.
112. Kvist, E. E., Al-Shurbaji, A., Dahl, M.-L., Nordin, C., Alván, G., Ståhle, L., 2001, Quantitative pharmacogenetics of nortriptyline. A novel approach, Clin. Pharmacokinet. 40(11), 869-877.
113. Lane, H. Y., Hu, O. Y. P., Jann, M. W. et al., 1997, Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients, Psychiatry Res. 69, 105-111.
114. Lee, C. R., Goldstein, J. A., Pieper, J. A., 2002, Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data, Pharmacogenetics. 12, 251-263.
115. Lemoine, A., Gautier, J. C., Azoulay, D., Kiffel, L., Belloc, C., Guengerich, F. P., Maurel, P., Beaune, P., Leroux, J. P., 1993, Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver, Mol. Pharmacol. 43, 827-832.
116. Lessard, E., Yessine, M. A., Hamelin, B. A., O'Hara, G., LeBlanc, J., Turgeon, J., 1999, Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans, Pharmacogenetics. 9, 435-443.
117. Linnet, K., Olesen O. V., 1997, Metabolism of clozapine by cDNA expressed human cytochrome P450 enzymes, Drug Metab. Dispos. 25, 1379-1382.
118. Linnet, K., Wiborg, O., 1996, Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism, Clin. Pharmacol. Ther. 60, 41-47.
119. Linnet, K., Wiborg, O., 1996, Influence of CYP2D6 genetic polymorphism on ratios of steady-state serum concentrations to dose of the neuroleptic zuclopenthixol. Ther. Drug. Monit. 18, 629-634.
120. Liu, Z.-Q., Cheng, Z.-N., Huang, S.-L., Chen, X.-P., Ou-Yang, D.-S., Jiang, C.-H., Zhou, H.-H., 2001, Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects, J. Clin. Pharmacol. 52, 96-99.
121. Liu, Z.-Q., Shu, Y., Huang, S.-L., Wang, L.-S., He, N., Zhou, H.-H., 2001, Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes, Acta. Pharmacol. Sin. 22(1), 85-90.
122. Liu, Z.-Q., Zhu, B., Tan, Y.-F., Tan, Z.-R., Wang, L.-S., Huang, S.-L., Shu, Y., Zhou, H.-H., 2001, O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes, J. Pharmacol. Exp. Ther. 299, 105-111.
123. Llerena, A., Alm, C., Dahl, M. L. et al., 1992, Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype, Ther. Drug Monit. 14, 92-97.
124. Llerena, A., Dahl, M. L., Ekqvist, B. et al., 1992, Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers, Ther. Drug Monit. 14, 261-264.
125. Llerena, A., Dorado, P., Berecz, R., González, A. P., Cáceres, M. C., 2003, Influence of CYP2D6 and CYP2C9 genotypes on fluoxetine plasma concentrations in psychiatric patients: European Collaboration: Towards Drug Development and Rational Drug Therapy, eds. F. C. Tulunay, M. Orme, Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics, Istanbul, June 24-28.
126. Lucas, R. A., Gilfillan, D. J., Bergstrom, R. F., 1998, A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanisms, Eur. J. Clin. Pharmacol. 54, 639-643.
127. Mäenpää, J., Wrightson, S., Bergstrom, R. et al., 1997, Pharmacokinetic (Pk) and pharmacodynamic (Pd) interactions between fluvoxamine and olanzapine, Clin. Pharmacol. Ther. 61, 225.
128. Mahgoub, A., Idle, J. R., Dring, L. G., et al., 1977, Polymorphic hydroxylation of debrisoquine in man, Lancet 2, 584-586.
129. Mannens, G., Huang, M. L., Meuldermans, W. et al., 1993, Absorption, metabolism, and excretion of risperidone in humans, Drug Metab. Dispos. 21, 1134-1141.
130. Margolis, J. M., O'Donnell, J. P., Mankowski, D. C., Ekins, S., Obach, R. S., 2000, (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes, Drug. Metab. Dispos. 28, 1187-1191.
131. Markowitz, J. S., Devane, C. L., 1999, Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentrations, J. Clin. Psychopharmacol. 19, 289-291.
132. Mellström, B., Bertilsson, L., Lou, Y. C., Säwe, J., Sjöqvist, F., 1983, Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation, Clin. Pharmacol. Ther. 34, 516-520.
133. Mellström, B., Säwe, J., Bertilsson, L., Sjöqvist, F., 1986, Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers, Clin. Pharmacol. Ther. 39, 369-371.
134. Meyer, J. W., Woggon, B., Baumann, P. et al., 1990, Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type, Eur. J. Clin. Pharmacol. 39, 613-614.
135. Miceli, J. J., Anziano, R. J., Robarge, L., Hansen, R. A., Laurent, A., 2000, The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers, Br. J. Clin. Pharmacol. 49(Suppl. 1), 65s-70s.
136. Miceli, J. J., Smith, M., Robarge, L., Morse, T., Laurent, A., 2000, The effects of ketoconazole on ziprasidone pharmacokinetics: a placebo-controlled crossover study in healthy volunteers, Br. J. Clin. Pharmacol. 49(Suppl. 1), 71s-76s.
137. Mihara, K., Otani, K., Suzuki A., Yasui, N., Nakano, H., Meng, X., Ohkubo T., Nagasaki T., Kaneko, S., Tsuchida, S., Sugawara, K.,. Gonzalez, F. J., 1997, Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine, Psychopharmacology (Berl) 133, 95-98.
138. Mihara, K., Otani, K., Tybring, G., Dahl, M. L., Bertilsson, L., Kaneko, S., 1997, The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients, J. Clin. Psychopharmacol. 17, 467-471.
139. *10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia, Clin. Pharmacol. Ther. 65, 291-294.
140. Mihara, K., Suzuki, A., Kondo, T. et al., 2000, Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia, Ther. Drug Monit. 22, 245-249.
141. Miners, J. O., Birkett, D. J., 1998, Cytochrome P4502C9: an enzyme of major importance in human drug metabolism, Br. J. Clin. Pharmacol. 45, 525-538.
142. Morinobu, S., Tanaka, T., Kawakatsu, S., Totsuka, S., Koyama, E., Chiba, K., Ishizaki, T., Kubota, T., 1997, Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy, Psychiatry. Clin. Neurosci. 51, 253-257.
143. Morita, S., Shimoda, K., Someya, T., Yoshimura, Y., Kamijima, K., Kato, N., 2000, Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline, J. Clin. Psychopharmacol. 20, 141-149.
144. Nakajima, M., Yokoi, T., Mizutani, M. et al., 1999, Genetic polymorphism in the 5'-Flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans, J. Biochem. 125, 803-808.
145. Nelson, D. R., Koymans, L., Kamataki, T. et al., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics 6, 1-42.
146. Nordin, C., Bertilsson, L., 1995, Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline, Clin. Pharmacokinet. 28, 26-40.
147. Nordin, C., Siwers, B., Benitez, J., Bertilsson, L., 1985, Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients-relationship to the debrisoquine hydroxylation metabolic ratio, Br. J. Clin. Pharmacol. 19, 832-835.
148. Nyberg, S., Farde, L., Halldin, C. et al., 1995, D2 Dopamine receptor occupancy during low-dose treatment with haloperidol decanoate, Am. J.
149. Ohmori, O., Suzuki, T., Kojima, H. et al., 1998, Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics, Schizophr. Res. 32, 107-113.
150. Olesen, O. V., Licht, R. W., Thomsen, E. et al., 1998, Serum concentrations and side effects in psychiatric patients during risperidone therapy, Ther. Drug Monit. 20, 380-384.
151. Olesen, O. V., Linnet, K., 1999, Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication, Ther. Drug Monit. 21, 87-90.
152. Olesen, O. V., Linnet, K., 2000, Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine, Br. J. Clin. Pharmacol. 50, 563-571.
153. Otani, K., Ishida M., Kaneko, S., Mihara, K., Ohkubo, T., Osanai, T., Sugawara, K., 1996, Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, Ther. Drug Monit. 18, 164-167.
154. Otton, S. V., Ball, S. E., Cheung, S. W., Inaba, T., Rudolph, R. L., Sellers, E. M., 1996, Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br. J. Clin. Pharmacol. 41, 149-156.
155. Özdemir, V., Kalow, W., Okey, A. B. et al., 2001, Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C? A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine, J. Clin. Psychopharmacol. 21, 603-607.
156. Özdemir, V., Naranjo, C. A., Herrmann, N., Reed, K., Sellers, E. M., Kalow, W., 1997, Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo, Clin. Pharmacol. Ther. 62, 334-347.
157. Özdemir, V., Tyndale, R. F., Reed, K., Herrmann, N., Sellers, E. M., Kalow, W., Naranjo, C. A., 1999, Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers, J. Clin. Psychopharmacol. 19, 472-475.
158. Pan, L., Belpaire, F. M., 1999, In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol, Eur. J. Clin. Pharmacol. 55, 599-604.
159. Pan, L., Vander Stichele, R., Rosseel, M. T. et al., 1999, Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients, Ther. Drug Monit. 21, 489-497.
160. Pirmohamed, M., Williams, D., Madden, S. et al., 1995, Metabolism and bioactivation of clozapine by human liver in vitro, J. Pharmacol. Exp. Ther. 272, 984-990.
161. Pollock, B. G., Mulsant, B. H., Sweet, R. A. et al., 1995, Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia, Psychopharmacol. Bulletin 31, 327-331.
162. Prakash, C., Kamel, A., Cui, D. et al., 2000, Identification of the major human liver cytochrome P450 isoform (s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions, Br. J. Clin. Pharmacol. 49(Suppl I), 35s-42s.
163. Preskorn, S. H., 1993, Pharmacokinetics of antidepressants: Why and how they are relevant to treatment, J. Clin. Psychiatry. 54(9), 14-34.
164. Raaska, K., Neuvonen, P. J., 1998, Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole, Eur. J. Clin. Pharmacol. 54, 167-170.
165. Rasmussen, B. B., Brøsen, K., 2000, Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?, Ther. Drug. Monit. 22(2), 143-154.
166. Relling, M. V., Lin, J. S., Ayers, G. D., Evans, W. E., 1992, Racial and gender differences in N-acetyltransferase, xanthine oxidase and CYP1A2 activities, Clin. Pharmacol. Ther. 52, 643-658.
167. Ring, B. J., Eckstein, J. A., Gillespie, J. S., Binkley, S. N., Vandenbranden M., Wrighton, S. A., 2001, Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine, J. Pharmacol. Exp. Ther. 297, 1044-1050.
168. Ring, B. J., Catlow, J., Lindsay, T. J. et al., 1996, Identification of the human cytochrome P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine, J. Pharmacol. Exp. Ther. 276, 658-666.
169. Rochat, B., Amey, M., Gillet, M., Meyer, U. A., Baumann, P., 1997, Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes, Pharmacogenetics 7, 1-10.
170. Roh, H. K., Chung, J. Y., Oh, D. Y. et al., 2001, Plasma concentrations of haloperidol and its reduced metabolite are related to the CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients, Br. J. Clin. Pharmacol. 52, 265-271.
171. Rotzinger, S., Fang, J., Coutts, RT., Baker, G. B., 1998, Human CYP2D6 and metabolism of m-chlorophenylpiperazine, Biol. Psychiatry 44, 1185-1191.
172. Sachse, C., Brockmöller, J., Bauer, S., Roots, I., 1997, Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences, Am. J. Hum. Genet. 60, 284-295.
173. Sachse, C., Brockmöller, J., Bauer, S. et al., 1999, Functional significance of a C? A polymorphism in Intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine, Br. J. Clin. Pharmacol. 47, 445-449.
174. Sachse, C., Schmider, J., Kanitz, P. et al., 2000, Frequency of CYP2D6 genotypes in schizophrenic patients and relation to antipsychotic therapy. Proceedings of the VII World Conference on Clinical Pharmacology and Therapeutics & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics. Florence, Italy.
175. Sata, F., Sapone, A., Elizondo, G. et al., 2000, CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity, Clin. Pharmacol. Ther. 67, 48-56.
176. Schulze, T. G., Schumacher, J., Muller, D. J. et al., 2001, Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia, Am. J. Med. Genet. 105, 498-501.
177. Scordo, M. G., Spina, E. Dahl, M-L., Gatti, G., Perucca, E., 2003, Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on plasma levels of fluoxetine and norfluoxetine enantiomers: European Collaboration: Towards Drug Development and Rational Drug Therapy, eds. F. C. Tulunay, M. Orme, Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics, Istanbul, June 24-28.
178. Scordo, M. G., Aklillu, E., Yasar, U., Dahl, M. L., Spina, E. Ingelman-Sundberg, M., 2001, Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population, Br. J. Clin. Pharmacol. 52, 447-450.
179. Scordo, M. G., Pengo, V. Spina, E. Dahl, M. L. Gusella, M. Padrini, R., 2002, Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance, Clin. Pharmacol. Ther. 72, 702-710.
180. Scordo, M. G., Spina, E., Facciolà, G. et al., 1999, Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone, Psychopharmacology 147, 300-305.
181. Scordo, M. G., Spina, E., Romeo, P. et al., 2000, CYP2D6 genotype and antipsychotic-induced extrapyramidal side-effecs in schizophrenic patients, Eur. J. Clin. Pharmacol. 56, 679-683.
182. Scordo, M. G., Spina, E., 2002, Cytochrome P450 polymorphisms and response to antipsychotic therapy, Pharmacogenomics 3, 201-218.
183. Shimada, T., Yamazaki, H., Mimura, M. et al., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J. Pharmacol. Exp. Ther. 270, 414-423.
184. *10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients, Ther. Drug Monit. 122, 392-396.
185. Shimoda, K., Someya, T., Morita, S. et al., 1999, Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients, Ther. Drug Monit. 21, 293-296.
186. Sindrup, S. H., Brøsen, K., Gram, L. F., 1992, Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism, Clin. Pharmacol. Ther. 51, 288-295.
187. Sindrup, S. H., Brøsen, K., Gram, L. F., Hallas, J., Skjelbo, E., Allen, A., Allen, G. D., Cooper, S. M., Mellows, G., Tasker, T. C. G., Zussman, B. D., 1992, The relationship between paroxetine and the sparteine oxidation polymorphism, Clin. Pharmacol. Ther. 51, 278-287.
188. Sindrup, S. H., Brøsen, K., Hansen, M. G., Aaes-Jorgensen, T., Overo, K. F., Gram, L. F., 1993, Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms, Ther. Drug. Monit. 15, 11-17.
189. Skjelbo, E., Brøsen, K., Hallas, J., Gram, L. F., 1991, The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine, Clin. Pharmacol. Ther. 49, 18-23.
190. Someya, T., Suzuki, Y., Shimoda, K. et al., 1999, The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population, Psychiatry and Clinical Neurosciences 53, 593-597.
191. Spigset, O., Axelsson, S., Norström, Å., Hägg, S., Dahlqvist, R., 2001, The major fluvoxamine metabolite in urine is formed by CYP2D6, Eur. J. Clin. Pharmacol. 57, 653-658.
192. Spigset, O., Carleborg, L., Hedenmalm, K., Dahlqvist, R., 1995, Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans, Clin. Pharmacol. Ther. 58, 399-403.
193. Spigset, O., Granberg, K., Hagg, S., Norstrom, A., Dahlqvist, R., 1997, Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms, Eur. J. Clin. Pharmacol. 52, 129-133.
194. Spigset, O., Hägg, S., Söderström, E., Dahlqvist, R., 1999, Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance, Eur. J. Clin. Pharmacol. 54, 943-946.
195. Spigset, O., Hedenmalm, K., Dahl, M.-L., Wiholm, B.-E., Dahlqvist, R., 1997, Seizures and myoclonus, associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors, Acta. Psychiatr. Scand. 96, 379-384.
196. Spina, E., Ancione, M., Di Rosa, A. E. et al., 1992, Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects, Eur. J. Clin. Pharmacol. 42, 347-348.
197. Spina, E., Avenoso, A., Facciolà, G. et al., 2000, Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate, Ther. Drug Monit. 22, 481-485.
198. Spina, E., Avenoso, A., Facciolà, G. et al., 2001, Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia, Psychopharmacology 153, 238-243.
199. Spina, E., Avenoso, A., Facciolà, G. et al., 1998, Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia, Int. Clin. Psychopharmacol. 13, 141-145.
200. Spina, E., Avenoso, A., Facciolà, G., Scordo, M. G., Ancione, M., Madia, A., 2001, Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine, Ther. Drug Monit. 23, 223-227.
201. Spina, E., Avenoso, A., Salemi, M. et al., 2000, Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline, Pharmacopsychiatry 33, 213-217.
202. Spina, E., Avenoso, A., Scordo, M. G. et al., 2002, Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction, J. Clin. Psychopharmacol. 22, 419-423.
203. Spina, E., Gitto, C., Avenoso, A., Campo, G. M., Caputi, A. P., Perucca, E., 1997, Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study, Eur. J. Clin. Pharmacol. 51, 395-398.
204. Spina, E., Scordo, M. G., Avenoso, A., Perucca, E., 2001, Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity, J. Clin. Psychopharmacol. 21, 108-109.
205. Spina, E., Steiner, E., Ericsson, O., Sjöqvist, F., 1987, Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype, Clin Pharmacol Ther 41, 314-319.
206. Spina, E., Sturiale, V., Valvo, S. et al., 1992, Debrisoquine oxidation phenotype and neurolepticinduced dystonic reactions, Acta Psychiatr. Scand. 86, 364-366.
207. Störmer, E., Von Moltke, L. L., Shader, R. I., Greenblatt, D. J., 2000, Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4, Drug. Metab. Dispos. 28, 1168-1175.
208. Suzuki, A., Otani, K., Mihara, K. et al., 1997, Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients, Pharmacogenetics 7, 415-418.
209. Tamminga, W. J., Wemer, J., Oosterhuis, B., De Boer, Vranckx, A. S., Drenth, B. F. H., De Zeeuw, De Leij, R. A. L. F. M. H., Jonkman, J. H. G., 2003, Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study, Eur. J. Clin. Pharmacol. 59, 57-64.
210. Task Force Laboratory Tests in Psychiatry, 1985, Tricyclic antidepressants-blood level measurements and clinical outcome: an APA Task Force report. Task Force on the Use of Laboratory Tests in Psychiatry, Am. J. Psychiatry. 142, 155-162.
211. Taylor, D., Bodani, M., Hubbeling, A., Murray, R., 1999, The effect of nefazodone on clozapine plasma concentrations, Int. Clin. Psychopharmacol. 14, 185-187.
212. Tucker, G. T., Silas, J. H., Iyun, A. O. et al., 1977, Polymorphic hydroxylation of debrisoquine, Lancet 2, 718.
213. Van Beijsterveldt, L. E. C., Geerts, R. J. F., Leysen, J. E. et al., 1994, The regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat, Psychopharmacology 114, 53-62.
214. Van Der Weide, J., Steijns, L. S., Van Weelden, M. J., 2003, The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement, Pharmacogenetics 13, 169-172.
215. Veefkind, A. H., Haffmans, P. M. J., Hoencamp, E., 2000, Venlafaxine serum levels and CYP2D6 genotype, Ther. Drug. Monit. 22, 202-208.
216. Von Bahr, C., Movin, G., Nordin, C. et al., 1991, Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype, Clin. Pharmacol. Ther. 49, 234-240.
217. Von Moltke, L. L., Greenblatt, D. J., Giancarlo, G. M., Granda, B. W., Harmatz, J. S., Shader, R. I., 2001, Escitalopram (S-citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram, Drug Metab. Dispos. 29, 1102-1109.
218. Wang, J.-H., Liu, Z.-Q., Wang, W., Chen, X.-P., Shu, Y., He, N., Zhou, H.-H., 2001, Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19, Clin. Pharmacol. Ther. 70, 42-47.
219. Wetzel, H., Anghelescu, I., Szegedi, A. et al., 1998, Pharmacokinetic interaction of clozapine with selective serotonin re-uptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study, J. Clin. Psychopharmacol. 18, 2-9.
220. Wienkers, L. C., Allievi, C., Hauer, M. J., Wynalda, M. A., 1999, Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes, Drug. Metab. Dispos. 27, 1334-1340.
221. Xu, Z.-H., Wang, W., Zhao, X.-J., Huang, S.-L., Zhu, B., He, N., Shu, Y., Liu, Z.-Q., Zhou, H.-H., 1999, Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes, J. Clin. Pharmacol. 48, 416-423.
222. Yasar, U., Forslund-Bergengren, C., Tybring, G. et al., 2002, Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype, Clin. Pharmacol. Ther. 71, 89-98.
223. Yasui, N., Kondo, T., Otani K. et al., 1999, Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism, J. Clin. Psychopharmacol. 19, 149-154.
224. Yasui, N., Otani, K., Kaneko, S., Ohkubo, T., Osanai, T., Ishida, M., Mihara, K., Kondo, T., Sugawara, K., Fukushima, Y., 1995, Inhibition of trazodone metabolism by thioridazine in humans, Ther. Drug. Monit. 17, 333-335.
225. Yasui-Furukori, N., Hidestrand, M., Spina E. et al., 2001, Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes, Drug Metab. Dispos. 29, 1263-1268.
226. *10 genotype of Korean Subjects, Clin. Pharmacol. Ther. 67(5), 567-576.
227. Yoshii, K., Kobayashi K., Tsumuji, M. et al., 2000, Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes, Life Sciences 67, 175-184.
228. Yue, Q. Y., Zhong, Z. H., Tybring, G., Dalen, P., Dahl, M.-L., Bertilsson, L., Sjöqvist, F., 1998, Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes, Clin. Pharmacol. Ther. 64, 384-390.